Core Viewpoint - Yifeng Pharmacy (603939.SH) reported a slight increase in revenue and a notable rise in net profit for the first three quarters of 2025, indicating stable growth in its financial performance [1] Financial Performance - The company achieved a revenue of 17.286 billion yuan for the first three quarters, reflecting a year-on-year growth of 0.39% [1] - The net profit attributable to shareholders reached 1.225 billion yuan, marking a year-on-year increase of 10.27% [1] - The non-recurring net profit was reported at 1.188 billion yuan, which represents a year-on-year growth of 8.80% [1] - Basic earnings per share stood at 1.01 yuan [1]

Core Insights - Yifeng Pharmacy (603939) reported its Q3 2025 financial results, showing a revenue of 5.564 billion yuan, which represents a year-on-year increase of 1.97% [1] - The net profit for Q3 2025 was 345 million yuan, reflecting a year-on-year growth of 10.14% [1] - For the first three quarters of 2025, the total revenue reached 17.286 billion yuan, marking a year-on-year increase of 0.39% [1] - The net profit for the first three quarters was 1.225 billion yuan, with a year-on-year growth of 10.27% [1]

Group 1 - Yifeng Pharmacy reported a revenue of approximately 17.286 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 0.39% [1] - The net profit attributable to shareholders of the listed company was approximately 1.225 billion yuan, showing a year-on-year increase of 10.27% [1] - Basic earnings per share reached 1.01 yuan, which is a year-on-year increase of 9.78% [1] Group 2 - As of the report, Yifeng Pharmacy has a market capitalization of 30.9 billion yuan [2]

Core Viewpoint - Yifeng Pharmacy (603939.SH) reported a year-on-year increase in revenue and net profit for Q3 2025, indicating positive financial performance and growth potential in the pharmaceutical retail sector [1] Financial Performance - The company's operating revenue for Q3 2025 reached 5.564 billion yuan, representing a year-on-year increase of 1.97% [1] - The net profit attributable to shareholders of the listed company was 345 million yuan, showing a year-on-year increase of 10.14% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 331 million yuan, reflecting a year-on-year increase of 8.08% [1]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-103 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于2025年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主 板上市公司 2025 年第三季度报告披露工作的重要提醒》相关要求，现将益丰 大药房连锁股份有限公司（以下简称"公司"）2025 年第三季度主要经营数据披 露如下： 一、报告期末主要经营数据 | | | 幅度(%) | | | --- | --- | --- | --- | | 总资产 | 26,071,387,113.50 | 27,974,736,950.35 | -6.80 | | 归属于上市公司 | | | | | 股东的所有者权 | 11,177,628,791.76 | 10,725,687,023.42 | 4.21 | | 益 | | | | ...

Financial Performance - Total revenue for Q3 2025 reached CNY 5,564,080,298.18, an increase of 1.97% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 344,509,955.35, reflecting a growth of 10.14% year-over-year[3] - The total profit for the period was CNY 506,365,892.34, up by 12.90% from the previous year[3] - Basic earnings per share for the quarter stood at CNY 0.28, a rise of 7.69% compared to the same quarter last year[4] - Total operating revenue for the first three quarters of 2025 reached ¥19,024,372,147.87, an increase from ¥18,703,468,518.23 in the same period of 2024, reflecting a growth of approximately 1.71%[23] - Net profit attributable to shareholders of the parent company was ¥1,224,555,838.55, up from ¥1,110,500,691.55, representing an increase of about 10.26%[20] - Operating profit for the period was ¥1,786,801,453.44, compared to ¥1,585,544,439.53, indicating a growth of approximately 12.67%[19] - Total comprehensive income for the period was ¥1,368,940,098.23, compared to ¥1,109,047,791.02, marking an increase of about 23.39%[20] - Basic earnings per share increased to ¥1.01 from ¥0.92, reflecting a growth of approximately 9.78%[20] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was CNY 2,267,211,017.81, down by 32.16%[3] - The net cash flow from operating activities decreased to ¥2,267,211,017.81 from ¥3,341,774,378.18, a decline of about 32.23%[23] - The net cash flow from investing activities was -363,176,077.84, compared to -3,670,397,674.23 in the previous period, indicating a significant improvement[24] - The net cash flow from financing activities was -2,075,775,121.25, a substantial increase in outflow compared to -90,663,355.34 last year[24] - Cash outflow for investing activities totaled 22,981,387,474.34, compared to 16,089,737,685.38 in the prior period, reflecting increased investment[24] - Cash outflow for financing activities was 2,077,528,121.25, up from 1,901,026,355.34, indicating higher financing costs[24] - The cash inflow from investment activities was 22,618,211,396.50, compared to 12,419,340,011.15 in the previous period, showing a significant increase[24] - The company reported a cash outflow of 914,684,834.87 for dividend distribution, which increased from 604,739,986.11 last year[24] - The cash and cash equivalents decreased by 171,740,181.28 during the period, compared to a decrease of 419,286,651.39 in the previous year[24] Assets and Liabilities - The company's total assets decreased by 6.80% to CNY 26,071,387,113.50 compared to the end of the previous year[4] - As of September 30, 2025, the total assets of the company amounted to RMB 26,071,387,113.50, a decrease from RMB 27,974,736,950.35 at the end of 2024, representing a decline of approximately 6.8%[14] - The company's total liabilities decreased to RMB 14,188,944,678.91 from RMB 16,581,173,472.42, indicating a reduction of about 14.4%[16] - The cash and cash equivalents as of September 30, 2025, were RMB 3,118,997,451.69, down from RMB 3,578,925,577.22, reflecting a decrease of approximately 12.9%[14] - The company's total equity increased to RMB 11,882,442,434.59 from RMB 11,393,563,477.93, marking an increase of approximately 4.3%[16] - The company's accounts receivable decreased to RMB 1,469,423,541.96 from RMB 2,123,984,911.43, a decline of about 30.8%[14] - The company's short-term borrowings decreased to RMB 20,017,777.78 from RMB 30,026,388.89, a reduction of approximately 33.5%[15] - The company's long-term borrowings remained stable, with total bonds payable at RMB 1,638,776,478.50, slightly increasing from RMB 1,601,308,876.07[16] Store Operations - The company opened 137 new stores and closed 440 stores in the first nine months of 2025, resulting in a total of 14,666 stores at the end of the reporting period, a net decrease of 18 stores year-over-year[13] - The company reported a total of 4,097 franchise stores included in the total store count as of September 30, 2025[13] Other Financial Metrics - Non-recurring gains and losses for the quarter totaled CNY 13,704,329.41, with a year-to-date total of CNY 36,632,913.44[7] - The weighted average return on equity was 3.35% for the quarter, compared to 11.05% in the previous year[4] - Research and development expenses were ¥21,511,803.30, down from ¥25,185,648.10, showing a decrease of approximately 14.66%[19] - Total operating costs decreased to ¥15,631,502,380.85 from ¥15,712,009,022.92, a reduction of about 0.51%[19] - Other income increased to ¥52,760,114.25 from ¥40,942,345.23, representing a growth of approximately 28.93%[19] - The company reported a net investment income of ¥99,769,501.43, up from ¥76,803,405.41, indicating an increase of about 30.00%[19] Accounting Standards - The company did not apply new accounting standards starting from 2025[25]

Core Insights - The company reported third-quarter revenue of 5.564 billion, representing a year-on-year increase of 1.97% [1] - The net profit for the third quarter was 345 million, showing a year-on-year growth of 10.14% [1] - For the first three quarters, the total revenue reached 17.286 billion, with a year-on-year increase of 0.39% [1] - The net profit for the first three quarters was 1.225 billion, reflecting a year-on-year growth of 10.27% [1] Financial Performance - Third-quarter revenue: 5.564 billion, up 1.97% year-on-year [1] - Third-quarter net profit: 345 million, up 10.14% year-on-year [1] - Year-to-date revenue (first three quarters): 17.286 billion, up 0.39% year-on-year [1] - Year-to-date net profit (first three quarters): 1.225 billion, up 10.27% year-on-year [1]

Core Insights - The event "Heartfelt Discount Festival" launched by Omron Healthcare (China) and Shanghai Yifeng Pharmacy aims to promote high-quality health products and services while raising awareness about stroke prevention [1][3]. Group 1: Stroke Awareness and Prevention - Stroke, known as a leading health threat, has high incidence, mortality, and disability rates, creating significant burdens on patients and society [3]. - Omron focuses on hypertension management as a key strategy for stroke prevention, promoting a shift from disease treatment to proactive health management [3]. Group 2: Collaboration and Community Health - Yifeng Pharmacy, a major national retail pharmacy chain, collaborates with Omron to enhance public health management through professional services and quality products [5]. - The "Heartfelt Discount Festival" offers promotional pricing on health devices like blood pressure monitors and nebulizers, making health management more accessible for families [5]. Group 3: Future Vision and Commitment - Omron's vision is to make medical devices user-friendly and reliable, aiming to extend health management concepts to more cities and communities [7]. - The company is committed to providing professional and trustworthy health care to every family, reinforcing its dedication to public health [7].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-102 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于募集资金委托理财进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次赎回产品基本情况 | 产品名称 | 利多多公司稳利 期 25JG3300 | | | --- | --- | --- | | 受托方名称 | 上海浦东发展银行股份有限公司 | | | 购买金额 | 6,400.00 | 万元 | | 产品期限 | 天 89 | | | 产品名称 | 2025 | 年第 | 851 | 期公司结构性存款 | | --- | --- | --- | --- | --- | | 受托方名称 | | | 长沙银行股份有限公司 | | | 购买金额 | 2,125.00 | | 万元 | | | 产品期限 | 天 90 | | | | | 产品名称 | 2025 | 年第 | 852 | 期公 ...

Core Viewpoint - On October 27, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan [1] Summary by Category Restricted Share Unlocking - Xiamen Bank (601187) extended the lock-up period for 1.348 billion shares [1] - Guangzheng Eye Hospital (002524) released 2.2245 million shares under equity incentive restrictions [1] - Shapuaisi (603168) released 30,000 shares under equity incentive restrictions [1] - Yifeng Pharmacy (603939) released 195,000 shares under equity incentive restrictions [1] - Jihong Co., Ltd. (002803) released 1.98 million shares under equity incentive restrictions [1] - Mingyang Circuit (300739) released 1.2387 million shares under equity incentive restrictions [1] - Arrow Home (001322) released 800 million shares under pre-issue restrictions [1] - Ruichen Environmental Protection (301273) released 3.70125 million shares under pre-issue restrictions [1] - Jinchengzi (688291) released 6.9 million shares [1] - Weice Technology (688372) released 2.70328 million shares [1]